ClinicalTrials.gg
Not yet recruitingNCT06195111Updated Jan 8, 2024

A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study)

An observational study in Metastatic Colorectal Cancer, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-08.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University — 19 open to participants now, 20 under way, 2 of them phase 3. Colorectal Neoplasms · Second Affiliated Hospital, School of Medicine, Zhejiang University.

Started
2024
with 2 others
Observational
8 of 32
4 open now
Primary completion
2027-03
later than 11 of 19 live
Registered
20th of 32
by date

Among the 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University, this one is one of 3 that started in 2024, is one of 8 observational ones, reaches primary completion later than 11 of the 19 other live ones, and was the 20th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

19 of the 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Colorectal Neoplasms by Second Affiliated Hospital, School of Medicine, Zhejiang University, or all of them as a file.
02

Study summary

A real-world study of trifluridine/tipiracil containing regimen for the treatment of patients with metastatic colorectal cancer. A total of 200 patients planned to be enrolled.

Read the detailed description

This is a non-randomized, uncontrolled, multicenter real-world study. The total number of subjects is 200. The objective is to observe and evaluate the efficacy and safety of Trifluridine/Tipiracil alone or in combination with other therapies in the treatment of metastatic colorectal cancer in real-world environment. The primary endpoints is Progression-free survival (PFS). Secondary endpoints are overall survival (OS), Objective response rate(ORR), Disease control rate(DCR), progression-free survival (PFS), and Quality of life (QoL).

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients, being treated for mCRC with Trifluridine/Tipiracil-containing regimen.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:

  • Male and female patients with ≥18 years of age;
  • Patients with colorectal cancer confirmed by histopathology;
  • Be willing to use reliable methods and refrain from sperm donation throughout the study period and within 3 months after the last dose;
  • Voluntarily join the study and provide written to participate in the study;
  • Have traceable medical history during the treatment;
  • Doctor believe the patients can benefit from the study.

Exclusion criteria

Exclusion Criteria:

Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study:

  • Failure to sign ;
  • Patients with to Trifluridine/Tipiracil;
  • Female subjects who have a positive pregnancy test or are breastfeeding;
  • Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Trifluridine/Tipiracil

    Patients with metastatic colorectal cancer plan to recieve Trifluridine/Tipiracil-containing treatment will be enrolled in this study. The prescription all determined by doctor based on patient's situation.

    Drug: Trifluridine/Tipiracil

Interventions

  • DrugTrifluridine/Tipiracil

    This a rospective observational study. There is no treatment allocation. Patients administered Trifluridine/Tipiracil by prescription

    Also known as: TAS-102, FTD/TPI, Lonsurf

06

What researchers measure

Primary outcomes

  1. PFS (Progression-free survival)

    Progression-free survival defined as the time elapsed between the randomization and the date of radiologic tumour progression according to RECIST version 1.1 by investigator's judgement or death from any cause, whichever comes first.

    Time frame: Approximately 12 months

Secondary outcomes

  1. OS (Overall Survival)

    Overall survival defined as the observed time elapsed between the date of first treatment and the date of death due to any cause.

    Time frame: Approximately 12 months

  2. ORR(Objective response rate)

    Objective Response Rate defined as the proportion of patients with objective evidence of complete response (CR) or partial response (PR) according to RECIST version 1.1 criteria and using investigator's tumor assessment.

    Time frame: Approximately 12 months

  3. DCR (Disease control rate)

    Disease control rate defined as the proportion of patients with objective evidence of CR or PR or stable disease (SD) according to RECIST version 1.1 criteria and using investigator's tumor assessment.

    Time frame: Approximately 12 months

  4. Quality of life: EORTC QLQ-C30

    Assess patients health and activities using the European Organization for Research and Treatment of Cancer Core Quality of Life (EORTC QLQ-C30) module.

    Time frame: Approximately 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Mar 2027, 36 months later.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 36 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2023
First posted
Jan 8, 2024
StartEst.
Mar 1, 2024
Primary completionEst.
Mar 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Jan 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06195111
Responsible party
Sponsor
First posted
Jan 8, 2024
Start date
Mar 1, 2024 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jan 8, 2024

Study contacts

Ying Yuan, ph.D & MD
Contact
yuanying1999@zju.edu.cn
+86-13858193601
Dan Li, ph.D & MD
Contact
li_dan@zju.edu.cn
+86-15868405387

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion